PMV PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PMV PHARMACEUTICALS, INC. (PMVP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-11-12
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $554.00K, a 55300.00% increase year-over-year.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was -$11.00K, a 102.71% decline year-over-year.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $1.00K.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $406.00K, a 10050.00% increase year-over-year.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $987.00K, a 90.43% decline from fiscal 2021.
- PMV PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $10.32M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | |||
| 2024-09-30 | $554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $554.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$10.00K derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-K · filed 2024-02-29 | |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $11.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $10.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $406.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $987.00K 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $581.00K 10-Q · filed 2023-11-09 | |||
| 2022-03-31 | $10.35M 10-Q · filed 2023-05-10 | $10.35M derived: sum of 2 quarters · filed 2024-02-29 | $10.35M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.00K derived: sum of 2 quarters · filed 2024-02-29 | $10.32M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $10.31M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $10.31M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |